Azenta (NASDAQ:AZTA) vs. Quanterix (NASDAQ:QTRX) Head to Head Review

Quanterix (NASDAQ:QTRX) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Quanterix and Azenta, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1	2	0	0	1.67
Azenta	1	2	4	0	2.43

Quanterix presently has a consensus price target of $3.00, indicating a potential upside of 12.36%. Azenta has a consensus price target of $41.20, indicating a potential upside of 26.19%. Given Azenta’s stronger consensus rating and higher possible upside, analysts plainly believe Azenta is more favorable than Quanterix.

Valuation and Earnings

This table compares Quanterix and Azenta”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90 million	0.91	-$107.15 million	($2.63)	-1.02
Azenta	$593.82 million	2.41	-$55.76 million	($2.76)	-11.83

Azenta has higher revenue and earnings than Quanterix. Azenta is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Quanterix has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Azenta has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Insider & Institutional Ownership

86.5% of Quanterix shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Quanterix and Azenta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Azenta	-20.63%	1.18%	0.97%

Summary

Azenta beats Quanterix on 12 of the 14 factors compared between the two stocks.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

About Azenta

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.